Canadian best practice recommendations for the management of amyotrophic lateral sclerosis

TY - JOUR

T1 - Canadian best practice recommendations for the management of amyotrophic lateral sclerosis

AU - Shoesmith, Christen

AU - Abrahao, Agessandro

AU - Benstead, Tim

AU - Chum, Marvin

AU - Dupre, Nicolas

AU - Izenberg, Aaron

AU - Johnston, Wendy

AU - Kalra, Sanjay

AU - Leddin, Desmond

AU - O’Connell, Colleen

AU - Schellenberg, Kerri

AU - Tandon, Anu

AU - Zinman, Lorne

N1 - Funding Information: Competing interests: Christen Shoesmith, Aaron Izenberg, Wendy Johnston, Colleen O’Connell, Kerri Schellenberg and Lorne Zinman were members of a scientific advisory committee for Radicava (edaravone; Mitsubishi Tanabe Pharma Canada). Christen Shoesmith reports being a site principal investigator for several multicentre amyotrophic lateral sclerosis (ALS) clinical trials. In the last 36 months, Dr. Shoesmith has participated in clinical trials sponsored by Biogen, Cytokinetics, ALS Pharma and Orphazyme. Marvin Chum reports receiving a grant from Bernice Ramsay ALS Clinical Research Fellowship, outside the submitted work. Aaron Izenberg reports receiving personal fees from Biogen, Roche, Alnylam, Genzyme, Takeda and Mitsubishi Tanabe Pharma, outside the submitted work. No other competing interests were declared.

PY - 2020/11/16

Y1 - 2020/11/16

UR - http://www.scopus.com/inward/record.url?scp=85096259128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096259128&partnerID=8YFLogxK

U2 - 10.1503/cmaj.191721

DO - 10.1503/cmaj.191721

M3 - Article

C2 - 33199452

AN - SCOPUS:85096259128

SN - 0820-3946

VL - 192

SP - E1453-E1468

JO - CMAJ

JF - CMAJ

IS - 46

ER -